Literature DB >> 12469207

Determination of RNA expression for cholecystokinin/gastrin receptors (CCKA, CCKB and CCKC) in human tumors of the central and peripheral nervous system.

Florence Lefranc1, Carole Chaboteaux, Nathalie Belot, Jacques Brotchi, Isabelle Salmon, Robert Kiss.   

Abstract

Gastrin (G17) belongs to the cholecystokinin (CCK) peptide family widely distributed in the brain, and we were the first to show that it significantly modulates the growth and migration features of tumor astyrocytes. Conflictual data have been published as to whether CCKA, CCKB and CCKC receptors are, or are not, present in tumors of the central and peripheral nervous system (CPNS) in general, and in gliomas in particular. In the present study we employed polymerase chain reaction (PCR) on a series of 29 CNPS tumors, including 20 gliomas (17 astrocytic and 3 oligodendroglial tumors), 4 schwannomas and 5 meningiomas to investigate whether RNAs were present or absent in the case of these CCKA, CCKB and CCKC receptors. The presence of the three CCK receptor subtypes was also assayed on three experimental models, i.e. the U373 human glioma, the C6 rat glioma and the 9L rat gliosarcoma. The data show that 9/20 (45%) of the gliomas exhibited RNAs for the CCKB receptor as did the C6 rat glioma, 13/20 (65%) RNAs for the CCKC receptor as did the U373 human glioma and the 9L rat gliosarcoma. Of the 20 gliomas, 17 (85%) expressed RNAs for either the CCKB or the CCKC receptor (or both), a feature which was also observed in the experimental models. One schwannoma and one meningioma exhibited RNAs for the CCKB receptor, while 4/4 schwannomas and 4/5 meningiomas showed RNAs for the CCKC receptor. None of the gliomas, schwannomas or meningiomas exhibited RNAs for the CCKA receptor, which were found in the 9L rat gliosarcoma model only. These data emphasize that 85% of the gliomas under study and 86% (25/29) of the tumors of the central and peripheral nervous system exhibited CCKB and/or CCKC receptors. This therefore suggests an important role for gastrin in the biological development of these tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469207

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Meningiomas expressing and responding to cholecystokinin (CCK).

Authors:  Eftychia Oikonomou; Ana L Machado; Michael Buchfelder; Eric F Adams
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

2.  Coexpression of cholecystokinin-B/gastrin receptor and gastrin gene in human gastric tissues and gastric cancer cell line.

Authors:  Jian-Jiang Zhou; Man-Ling Chen; Qun-Zhou Zhang; Jian-Kun Hu; Wen-Ling Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

3.  MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation.

Authors:  Yong-Xi Song; Zhen-Yu Yue; Zhen-Ning Wang; Ying-Ying Xu; Yang Luo; Hui-Mian Xu; Xue Zhang; Li Jiang; Cheng-Zhong Xing; Yong Zhang
Journal:  Mol Cancer       Date:  2011-01-04       Impact factor: 27.401

4.  Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.

Authors:  Michal Grzmil; Yun Qin; Carina Schleuniger; Stephan Frank; Stefan Imobersteg; Alain Blanc; Martin Spillmann; Philipp Berger; Roger Schibli; Martin Behe
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.